Evobright signs cooperation agreement with world-leading experts

Today Evobright and the UKSH have signed a collaborative research agreement laying out their intention for a long term partnership. “With the research group of Prof. Dr. Daniela Wesch we have internationally renowned experts in the field of immuno-oncology and gamma delta T cells on our side. They have established the tools to precisely analyze the immune contents of a primary patients tumor and they have ex-vivo tumor models to translate the mode of action of a drug into the real world setting. This is a clear game changer in terms of predictivity of the efficacy of a drug and will allow us to benchmark our approach against the competition” says CEO Dr. Klaus-Peter Künkele. COO Dr. Christoph Baumann comments with a huge smile:” That we were additionally able to convince Prof. Dr. Matthias Peipp to join our efforts and to contribute to our drug design and scaffold optimization to implement our “Evobody platform” is of tremendous value and extends our expertise and abilities significantly.” Prof. Peipp has published >100 publication on (bispecific) therapeutic antibodies and is a renowned expert and consultant to multiple pharmaceutical companies.